BeOne Medicines (ONC) Non-Current Deferred Tax Liability (2016 - 2026)

BeOne Medicines (ONC) has 11 years of Non-Current Deferred Tax Liability data on file, last reported at $55.9 million in Q1 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability rose 29.59% year-over-year to $55.9 million in Q1 2026; TTM through Mar 2026 was $55.9 million, a 29.59% increase from a year earlier, with the FY2025 full-year figure at $53.2 million, up 26.67% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2026 stood at $55.9 million, up from $53.2 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for ONC reached as high as $55.9 million in Q1 2026 and fell as low as $14.2 million in Q1 2022.
• Historically, Non-Current Deferred Tax Liability has averaged $27.7 million across 5 years, with a median of $16.4 million in 2024.
• Across the five-year window, Non-Current Deferred Tax Liability retreated 18.18% in 2023 and soared 195.36% in 2025, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $24.6 million in 2022, then retreated by 18.18% to $20.1 million in 2023, then jumped by 108.9% to $42.0 million in 2024, then rose by 26.67% to $53.2 million in 2025, then advanced by 4.99% to $55.9 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $55.9 million in Q1 2026, $53.2 million in Q4 2025, and $47.1 million in Q3 2025.